Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$53.76 USD

53.76
22,196,871

+0.86 (1.63%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $65.16 in the latest trading session, marking a -0.49% move from the prior day.

Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use

by Zacks Equity Research

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

by Zacks Equity Research

Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.

The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance

by Zacks Equity Research

NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.

Mark Vickery headshot

Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).

Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?

by Zacks Equity Research

Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.

Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review

by Zacks Equity Research

Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.

FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug

by Zacks Equity Research

The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.

Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

by Zacks Equity Research

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%

by Zacks Equity Research

Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.

Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results

by Zacks Equity Research

Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.

Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up

by Zacks Equity Research

Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.

Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up

by Zacks Equity Research

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.

Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

Pfizer (PFE) Q1 Earnings Beat, COVID Jab Sales Down as Expected

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q1 earnings and sales. Revenues from its COVID-19 vaccine, Comirnaty declined, as expected.

Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales

by Zacks Equity Research

Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.

Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 3.54% and 2.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings

by Mark Vickery

Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.

Ahan Chakraborty headshot

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

by Ahan Chakraborty

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Should You Buy Bristol Myers Squibb (BMY) Ahead of Earnings?

by Zacks Equity Research

Bristol Myers Squibb (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx

by Zacks Equity Research

Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx are included in this Analyst Blog.